...
search icon
calc-img

CalciMedica, Inc. Common Stock, Common Stock

CALC

NAQ

$2.51

-$0.16

(-5.99%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$36.00M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
16.61K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.05 L
$6.26 H
$2.51

About CalciMedica, Inc. Common Stock, Common Stock

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCALCSectorS&P500
1-Week Return-5.99%-0.03%1.53%
1-Month Return-16.61%4.56%4.75%
3-Month Return-25.52%1.29%2.77%
6-Month Return-44.59%-3.54%12.18%
1-Year Return-48.25%1.59%22.34%
3-Year Return-85.99%13.55%38.91%
5-Year Return-98.91%40.85%80.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-395.00K519.00K52.00K58.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":76.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":10.02,"profit":true},{"date":"2023-12-31","value":11.18,"profit":true}]
Gross Profit-(395.00K)(519.00K)(52.00K)(58.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-39500000,"profit":false},{"date":"2021-12-31","value":-51900000,"profit":false},{"date":"2022-12-31","value":-5200000,"profit":false},{"date":"2023-12-31","value":-5800000,"profit":false}]
Gross Margin-(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses37.50M29.83M35.95M33.22M21.82M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":79.55,"profit":true},{"date":"2021-12-31","value":95.85,"profit":true},{"date":"2022-12-31","value":88.57,"profit":true},{"date":"2023-12-31","value":58.18,"profit":true}]
Operating Income(37.50M)(29.83M)(35.95M)(36.18M)(21.88M)[{"date":"2019-12-31","value":-3750200000,"profit":false},{"date":"2020-12-31","value":-2983200000,"profit":false},{"date":"2021-12-31","value":-3594700000,"profit":false},{"date":"2022-12-31","value":-3618000000,"profit":false},{"date":"2023-12-31","value":-2187500000,"profit":false}]
Total Non-Operating Income/Expense465.00K2.30M(1.23M)28.93M(12.59M)[{"date":"2019-12-31","value":1.61,"profit":true},{"date":"2020-12-31","value":7.95,"profit":true},{"date":"2021-12-31","value":-4.24,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-43.52,"profit":false}]
Pre-Tax Income(37.04M)(27.53M)(35.82M)(35.60M)(34.36M)[{"date":"2019-12-31","value":-3703700000,"profit":false},{"date":"2020-12-31","value":-2753100000,"profit":false},{"date":"2021-12-31","value":-3582100000,"profit":false},{"date":"2022-12-31","value":-3560500000,"profit":false},{"date":"2023-12-31","value":-3435700000,"profit":false}]
Income Taxes(393.00K)(538.00K)(2.00M)2.39M(109.89K)[{"date":"2019-12-31","value":-16.46,"profit":false},{"date":"2020-12-31","value":-22.53,"profit":false},{"date":"2021-12-31","value":-83.63,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-4.6,"profit":false}]
Income After Taxes(36.64M)(26.99M)(33.82M)(37.99M)(34.25M)[{"date":"2019-12-31","value":-3664400000,"profit":false},{"date":"2020-12-31","value":-2699300000,"profit":false},{"date":"2021-12-31","value":-3382400000,"profit":false},{"date":"2022-12-31","value":-3799300000,"profit":false},{"date":"2023-12-31","value":-3424710500,"profit":false}]
Income From Continuous Operations(37.04M)(27.53M)(35.82M)(35.60M)(34.36M)[{"date":"2019-12-31","value":-3703700000,"profit":false},{"date":"2020-12-31","value":-2753100000,"profit":false},{"date":"2021-12-31","value":-3582100000,"profit":false},{"date":"2022-12-31","value":-3560500000,"profit":false},{"date":"2023-12-31","value":-3435700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(37.04M)(27.53M)(35.82M)(35.60M)(34.36M)[{"date":"2019-12-31","value":-3703700000,"profit":false},{"date":"2020-12-31","value":-2753100000,"profit":false},{"date":"2021-12-31","value":-3582100000,"profit":false},{"date":"2022-12-31","value":-3560500000,"profit":false},{"date":"2023-12-31","value":-3435700000,"profit":false}]
EPS (Diluted)-(4.68)(23.66)(24.92)(25.59)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-468,"profit":false},{"date":"2021-12-31","value":-2366,"profit":false},{"date":"2022-12-31","value":-2492,"profit":false},{"date":"2023-12-31","value":-2559,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CALC
Cash Ratio 3.86
Current Ratio 4.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CALC
ROA (LTM) -87.15%
ROE (LTM) -128.26%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CALC
Debt Ratio Lower is generally better. Negative is bad. 0.44
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.56

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CALC
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 3.99
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is CalciMedica, Inc. Common Stock share price today?

CalciMedica, Inc. Common Stock (CALC) share price today is $2.51

Can Indians buy CalciMedica, Inc. Common Stock shares?

Yes, Indians can buy shares of CalciMedica, Inc. Common Stock (CALC) on Vested. To buy CalciMedica, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CALC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of CalciMedica, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of CalciMedica, Inc. Common Stock (CALC) via the Vested app. You can start investing in CalciMedica, Inc. Common Stock (CALC) with a minimum investment of $1.

How to invest in CalciMedica, Inc. Common Stock shares from India?

You can invest in shares of CalciMedica, Inc. Common Stock (CALC) via Vested in three simple steps:

  • Click on Sign Up or Invest in CALC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in CalciMedica, Inc. Common Stock shares
What is CalciMedica, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of CalciMedica, Inc. Common Stock (CALC) is $6.26. The 52-week low price of CalciMedica, Inc. Common Stock (CALC) is $2.05.

What is CalciMedica, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of CalciMedica, Inc. Common Stock (CALC) is 3.99

What is the Market Cap of CalciMedica, Inc. Common Stock?

The market capitalization of CalciMedica, Inc. Common Stock (CALC) is $36.00M

What is CalciMedica, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of CalciMedica, Inc. Common Stock is CALC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top